What is ganglioglioma?
A ganglioglioma is a slow-growing brain tumour made of two kinds of abnormal cells: nerve cells (ganglion cells) and support cells called glial cells. The name combines both: “ganglio” for the nerve cells and “glioma” for the glial cells.
Gangliogliomas are low-grade tumours. The World Health Organization (WHO) classifies them as CNS WHO grade 1, the least aggressive grade (Louis et al., 2021). They grow slowly and rarely spread.
They are most common in children, teenagers and young adults. Most develop in the temporal lobe, the part of the brain near the temples that is involved in memory and emotion.
The most typical symptom is epilepsy, often seizures that have been present for years and do not respond well to medicines. Gangliogliomas are the most common tumour found in people having epilepsy surgery (Blumcke et al., 2017).
Surgery to remove the tumour completely is the main treatment. It cures most people and, in many, also stops the seizures (Blumcke and Wiestler, 2002).
About a third of gangliogliomas carry a change in the BRAF gene called BRAF V600E. This matters because targeted tablets can help when the tumour cannot be fully removed.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of tumour | Low-grade mixed neuronal and glial (glioneuronal) brain tumour |
| WHO grade | CNS WHO grade 1 |
| How common | About 1-2% of brain tumours overall; more in children |
| Typical age | Children and young adults; most under 30 |
| Common sites | Temporal lobe; also other lobes, cerebellum, brainstem, spinal cord |
| Main symptom | Seizures (epilepsy) |
| Key gene change | BRAF V600E in about 20-50% |
| Main treatment | Complete surgical removal |
| Outlook | Excellent; long-term survival above 90% |
2. Causes and risk factors
The cause of ganglioglioma is not known. There are no known lifestyle or environmental causes.
Gene changes
Most gangliogliomas have a change in a gene that controls the MAPK signalling pathway, which tells cells when to grow.
| Gene change | How often | Notes |
|---|---|---|
| BRAF V600E | About 20-50% | The most common change; can be targeted with BRAF and MEK inhibitors |
| Other BRAF changes | Uncommon | Fusions and small insertions |
| FGFR1, FGFR2 changes | Uncommon | Also switch on the MAPK pathway |
| KRAS, NF1 and others | Rare | Found in a small number of tumours |
These changes happen only in the tumour. They are not inherited and are not passed to children.
In children, the BRAF V600E mutation has been linked with a higher chance of the tumour coming back after surgery (Dahiya et al., 2013).
Why gangliogliomas cause epilepsy
Gangliogliomas belong to a group called long-term epilepsy-associated tumours (LEATs). These tumours sit in the cortex, the outer layer of the brain where seizures start.
The abnormal nerve cells inside the tumour can be electrically active, and the brain tissue around the tumour can become irritable. Over time, seizures can also spread from a wider area. This is why surgery sometimes removes a small rim of brain tissue around the tumour, as well as the tumour itself.
In a large European study of more than 9,000 brain samples from epilepsy surgery, tumours were the second most common finding, and ganglioglioma was the most common tumour type (Blumcke et al., 2017).
Genetic conditions
Gangliogliomas are very rarely linked with inherited syndromes, such as neurofibromatosis type 1 or tuberous sclerosis. Almost all occur in people without these conditions.
3. How does it look
On MRI scans
MRI is the best test for showing a ganglioglioma.
| Feature | Typical appearance |
|---|---|
| Location | Outer part (cortex) of the temporal lobe in most cases |
| Structure | Often a fluid-filled cyst with a solid nodule in its wall |
| Solid part | Solid tumour without a cyst in some cases |
| Calcium | Calcium deposits are common and are seen well on CT |
| Contrast dye | The solid part often enhances (lights up) |
| Swelling (oedema) | Little or none around the tumour |
| Mass effect | Usually small; may thin the overlying skull bone if present for many years |
Under the microscope
| Feature | Description |
|---|---|
| Abnormal nerve cells | Large, misshapen (dysmorphic) ganglion cells, sometimes with two nuclei |
| Glial cells | Tumour astrocytes forming the growing part of the tumour |
| Background features | Rosenthal fibres, eosinophilic granular bodies, calcium deposits |
| Lymphocytes | Small immune cells clustered around blood vessels |
| Growth activity | Low; few dividing cells |
| Special stains | Neuronal markers (synaptophysin, neurofilament); CD34 positive in many; BRAF V600E stain positive in mutated tumours |
Related tumours
| Tumour | How it differs |
|---|---|
| Gangliocytoma | Contains only abnormal nerve cells, without the glial part |
| Desmoplastic infantile ganglioglioma | Very large cystic tumour in babies, usually under 2 years |
| Dysembryoplastic neuroepithelial tumour (DNET) | Another epilepsy-associated tumour with a different microscopic pattern |
| Pleomorphic xanthoastrocytoma | Also often BRAF V600E positive; usually more cellular |
| Pilocytic astrocytoma | Another grade 1 glioma; usually without abnormal nerve cells |
4. Symptoms
Common symptoms
- Seizures, in about 80-90% of people with temporal lobe tumours
- Focal seizures, such as strange feelings in the stomach, deja vu, fear, unusual smells or tastes
- Episodes of staring or unresponsiveness, sometimes with lip-smacking or fiddling movements
- Generalised seizures with stiffening and jerking
- Headaches
Seizures have often been present for months or years before the tumour is found, and they may not be controlled by anti-seizure medicines.
Symptoms by location
| Location | Possible symptoms |
|---|---|
| Temporal lobe | Seizures, memory problems, language difficulties |
| Frontal lobe | Seizures, changes in behaviour or personality, weakness |
| Cerebellum | Unsteadiness, clumsiness, headache, vomiting |
| Brainstem | Double vision, facial weakness, swallowing difficulty, weakness |
| Spinal cord | Back pain, weakness or numbness in the limbs, bladder problems |
Signs of raised pressure inside the head
Larger tumours or blockage of fluid flow can cause:
- Morning headaches
- Nausea and vomiting
- Blurred or double vision
- Drowsiness
When to seek medical advice
See a doctor if you or your child has a first seizure, seizures that are becoming more frequent, or persistent headaches with vomiting. Seek emergency help for a seizure lasting more than 5 minutes.
5. Diagnosis
| Test | Purpose |
|---|---|
| Neurological examination | Checks nerve function, strength, coordination and vision |
| MRI with contrast | Shows the tumour and its relationship to important brain areas |
| CT scan | Shows calcium and is useful in emergencies |
| EEG | Records the brain’s electrical activity and locates seizure activity |
| Surgery or biopsy | Provides tissue to confirm the diagnosis |
| Molecular testing | Looks for BRAF V600E and other gene changes |
| Neuropsychological testing | Assesses memory and thinking before epilepsy surgery |
For people with long-standing epilepsy, tests such as video-EEG monitoring and functional MRI help plan surgery that removes both the tumour and the surrounding seizure-producing brain tissue.
6. Treatment
Treatment is planned by a team including neurosurgeons, neurologists, epilepsy specialists and neuro-oncologists.
Surgery
Surgery is the main treatment.
| Approach | Notes |
|---|---|
| Gross total resection | Removal of the whole visible tumour; the best chance of cure and seizure control |
| Epilepsy surgery | May include removal of nearby brain tissue that triggers seizures |
| Awake surgery or brain mapping | Used when the tumour is near areas for speech or movement |
| Partial removal | When complete removal would be unsafe, for example in the brainstem |
After complete removal, about 8 in 10 people become seizure-free (Bonney et al., 2015). Shorter duration of epilepsy before surgery is linked with better seizure control.
Treatment when surgery cannot remove the whole tumour
| Treatment | Notes |
|---|---|
| Watch and wait | Regular MRI scans; many remaining tumours stay stable |
| Repeat surgery | If the tumour grows and can be safely removed |
| BRAF and MEK inhibitors | Dabrafenib with trametinib works well in BRAF V600E low-grade gliomas in children (Bouffet et al., 2023) |
| Other targeted drugs | Such as tovorafenib for some BRAF-altered paediatric low-grade gliomas |
| Chemotherapy | Carboplatin and vincristine, mainly in children |
| Radiotherapy | Rarely used, mainly for tumours that keep growing despite other treatments |
Anti-seizure medicines
Many people continue anti-seizure medicines for a period after surgery. If they remain seizure-free, medicines can often be reduced or stopped under specialist supervision.
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Before surgery | MRI, EEG and sometimes memory and language tests; a few days of video-EEG monitoring for epilepsy surgery |
| The operation | General anaesthetic; sometimes part of the operation is done awake to protect speech or movement |
| Hospital stay | Usually 3-7 days, including a short time in intensive care or a high-dependency unit |
| Recovery at home | Tiredness and headaches for several weeks; most people return to school or work within 1-3 months |
| Targeted tablets | Taken at home, with regular check-ups, blood tests and skin and eye checks |
Side effects
| Treatment | Possible side effects |
|---|---|
| Brain surgery | Headache, tiredness, infection, bleeding, temporary or permanent weakness, speech or memory problems |
| Temporal lobe surgery | Memory or word-finding difficulties; a small loss of the upper visual field |
| BRAF and MEK inhibitors | Fever, rash, tiredness, diarrhoea, skin and eye changes |
| Chemotherapy | Low blood counts, infections, nausea, nerve tingling |
7. Outlook (prognosis)
The outlook for most people with ganglioglioma is excellent.
| Measure | Approximate figures |
|---|---|
| Long-term survival | Above 90%; most people have a normal life expectancy |
| Seizure freedom after complete removal | About 80% |
| Recurrence after complete removal | Uncommon |
| Recurrence after partial removal | More likely; often slow and treatable |
In a 30-year study from the Mayo Clinic, complete removal was the most important factor for long-term tumour control (Compton et al., 2012).
For many people, the biggest long-term issue is seizure control rather than the tumour itself. Becoming seizure-free can greatly improve independence, schooling, work and driving. Children who have surgery early, before years of uncontrolled seizures, often have better learning and development.
Factors linked with a less favourable outcome
- Incomplete removal
- Location in the brainstem or spinal cord
- BRAF V600E mutation in some studies of children
- Long duration of epilepsy before surgery (for seizure control)
Rarely, a ganglioglioma can change into a more aggressive tumour. This is very uncommon, and tumours that look high grade are now often reclassified as other tumour types.
8. Follow-up
| Follow-up | Typical schedule |
|---|---|
| MRI scans | Every 3-6 months at first, then yearly, and less often over time |
| Neurology or epilepsy clinic | To review seizures and medicines |
| Neuropsychology | If there are memory or learning concerns |
| School or work support | Help with learning, concentration and fatigue |
9. Living with ganglioglioma
- Keep a seizure diary to help your team adjust treatment
- Follow driving rules; most countries require a seizure-free period before driving
- Take seizure safety precautions, such as showers instead of baths, until seizures are controlled
- Talk to teachers about extra support at school after surgery
- Get enough sleep, as tiredness can trigger seizures
- Ask about epilepsy support groups and brain tumour charities
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is a ganglioglioma cancer? | It is a tumour that grows slowly and rarely spreads; it is low grade and usually curable |
| Will the seizures stop after surgery? | For about 8 in 10 people, yes, if the tumour is completely removed |
| Is it inherited? | No, almost never |
| Will I need chemotherapy or radiotherapy? | Usually not; surgery alone is enough for most people |
| Can it come back? | It can, especially if some tumour remains, so regular scans are important |
| Can my child live a normal life? | Most children do very well and return to school and normal activities |
| Can I drive after surgery? | Usually after a seizure-free period set by local driving rules; ask your epilepsy team |
| Will I need to take seizure medicines for life? | Not always; many people who stay seizure-free after surgery can slowly come off medicines |
| Can I play sports? | Most sports are possible once you have recovered from surgery; avoid high-risk activities until seizures are controlled |
11. Questions to ask your care team
- Can the tumour be completely removed?
- Will surgery also treat the epilepsy?
- What are the risks to memory, speech or vision?
- Has the tumour been tested for BRAF V600E?
- When can anti-seizure medicines be reduced?
- How often will I need MRI scans?
- What support is available for school, work or driving?
Resources
- Blumcke, I. and Wiestler, O.D. (2002) ‘Gangliogliomas: an intriguing tumor entity associated with focal epilepsies’, Journal of Neuropathology and Experimental Neurology, 61(7), pp. 575-584.
- Blumcke, I. et al. (2017) ‘Histopathological findings in brain tissue obtained during epilepsy surgery’, New England Journal of Medicine, 377(17), pp. 1648-1656.
- Bonney, P.A. et al. (2015) ‘Seizure freedom rates and prognostic indicators after resection of gangliogliomas: a review’, World Neurosurgery, 84(6), pp. 1988-1996.
- Bouffet, E. et al. (2023) ‘Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations’, New England Journal of Medicine, 389(12), pp. 1108-1120.
- Compton, J.J. et al. (2012) ‘Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic’, Journal of Neurosurgery, 117(5), pp. 825-830.
- Dahiya, S. et al. (2013) ‘BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma’, Acta Neuropathologica, 125(6), pp. 901-910.
- Louis, D.N. et al. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- National Cancer Institute (2026) Childhood Astrocytomas, Other Gliomas, and Glioneuronal/Neuronal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.